• Contact us
Saturday, November 21, 2026
Register
Login
European Press
ADVERTISEMENT Handpicked deals on Amazon Discover useful products selected for our readers. Explore deals ›
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

New drug keeps advanced breast cancer in check far longer than chemo

29 October 2026
in Health
Reading Time: 3 mins read
A A
New drug keeps advanced breast cancer in check far longer than chemo
ShareShareShareShareShare


NEWYou can now listen to Fox News articles!
There may be a promising new treatment on the horizon for advanced breast cancer patients, according to developing research.Researchers are studying the cancer-killing drug trastuzumab rezetecan for those with ERBB2-low metastatic breast cancer, whose tumors have low levels of HER2, a protein that can help cancer cells grow.A phase 3 clinical trial called HORIZON-Breast06 sought to determine whether the drug works better than standard chemotherapy for patients with this cancer type.SHIFT IN CANCER SCREENING GUIDANCE HAS EXPERTS CLASHING OVER NEW GUIDANCEThe researchers analyzed 551 female patients across 73 hospitals in China who were randomly assigned to receive either the drug intravenously every three weeks, or the physician’s choice of chemotherapy. The study period lasted from June 2023 to August 2025. The median time without tumor growth on the drug was 16.4 months compared to 6.8 months with chemo. (iStock)The drug significantly delayed cancer progression compared with chemotherapy, giving patients more than a year before their cancer began growing again.The median time without tumor growth was 16.4 months compared to 6.8 months with chemo.FDA APPROVES ONCE-DAILY PILL FOR DEADLY CANCER AFTER PATIENTS’ SURVIVAL RATES NEARLY DOUBLEPatients who received trastuzumab rezetecan were 73% less likely to have their cancer worsen or die during the study than patients who received chemotherapy.The drug appeared to delay cancer progression in patients with both hormone receptor-positive and hormone receptor-negative breast cancer.The results were published in JAMA. The drug appeared to delay cancer progression in patients with both hormone receptor-positive and hormone receptor-negative breast cancer. (iStock)Tumors shrank in 75.5% of patients who received the drug, compared with 41.2% of those who received chemotherapy.At the 12-month mark, 90.6% of trastuzumab rezetecan patients were alive, compared to 81.4% of chemo patients.CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTERThe authors concluded that trastuzumab rezetecan provided “significant progression-free survival benefit over physician’s choice of chemotherapy in patients with ERBB2-low advanced breast cancer.”Loren Rourke, a Texas-based breast surgical oncologist and author in Texas, called the results “incredibly encouraging.” The researchers acknowledged that side effects occurred more frequently and “often required dose modification.” (iStock)”When you’re talking about women living with advanced breast cancer, those months matter,” Rourke, who was not involved in the study, told Fox News Digital. “They represent more time when the cancer is being held in check and potentially more opportunities to enjoy life without the disease getting worse.”What makes these findings especially exciting, according to the oncologist, is that the treatment showed benefits across different types of breast cancer.CLICK HERE FOR MORE HEALTH STORIES”It’s another important step forward, and it gives us genuine reason to be hopeful,” she said. “A treatment that can keep cancer from progressing for a longer period has the potential to make an enormous difference in a patient’s life.”While the drug may cause fewer serious lung problems than similar treatments, it was linked to other side effects, including anemia and other blood-related problems.”It’s another important step forward, and it gives us genuine reason to be hopeful.” Serious side effects occurred in more than 84% of patients who received the new drug, compared with nearly 68% of those who received chemotherapy.Rourke emphasized the importance of considering the side effects, “because more time without cancer progression doesn’t automatically mean better quality of life.” The researchers acknowledged that toxicity occurred more frequently and often required dose modification, although they said these effects were “generally manageable.” (iStock)”We need to better understand the side effects, particularly the significant decreases in blood counts that can lead to fatigue, anemia and increased risk of infection,” she said.The researchers acknowledged that toxicity occurred more frequently and often required dose modification, although they said these effects were “generally manageable.”TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZThe experts agreed that more research is needed.”As exciting as these findings are, there are still important questions we need to answer,” Rourke told Fox News Digital. “We know this treatment delayed cancer progression, but we don’t yet know whether it will help patients live longer. That’s an important distinction.”CLICK HERE TO DOWNLOAD THE FOX NEWS APP”It’s important to celebrate meaningful progress while making sure we’re asking the right questions about what comes next.” Angelica Stabile is a lifestyle reporter for Fox News Digital.

Credit: Source link

Previous Post

267,000 left the gym chain in 2025

Next Post

EastEnders fans are convinced they know who caused Zoe’s death

Recommended

Gritty road trip was enough to give Knicks back their mojo

Gritty road trip was enough to give Knicks back their mojo

21 November 2026

It can help to get away.  The Knicks left for their four-game road trip a bit unsettled, with questions circling...

Wordle today: The answer and hints for November 21, 2026

Wordle today: The answer and hints for November 21, 2026

21 November 2026

Today's Wordle answer should be easy to solve if you're a cardiologist.If you just want to be told today's word,...

Experimental pancreatic cancer drug doubles survival time in trial

Experimental pancreatic cancer drug doubles survival time in trial

21 November 2026

NEWYou can now listen to Fox News articles! Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth...

Rodeo Drive holiday lighting celebration marks 50 years

Rodeo Drive holiday lighting celebration marks 50 years

21 November 2026

Even the palm trees get dressed up for the holidays in Beverly Hills.  The annual Rodeo Drive Holiday Lighting Celebration...

Datenschutzinformationen

Disclaimer  Privacy Policy – EU  Imprint 

Join European Press

Contact us

What’s New Here!

  • Gritty road trip was enough to give Knicks back their mojo
  • Wordle today: The answer and hints for November 21, 2026
  • Experimental pancreatic cancer drug doubles survival time in trial
  • Rodeo Drive holiday lighting celebration marks 50 years

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

© 2026 European Press. All rights reserved.

European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video

© 2026 European Press. All rights reserved.

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?